Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Hepatol Int ; 18(2): 595-609, 2024 Apr.
Article in English | MEDLINE | ID: mdl-37843788

ABSTRACT

BACKGROUND: We conducted a meta-analysis and trial sequential analysis (TSA) to compare the therapeutic efficacy and adverse events (AEs) between the following treatment strategies for patients with hepatocellular carcinoma (HCC): TACE plus tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) (TACE + T + I) versus TACE plus TKIs (TACE + T). METHODS: We systematically searched PubMed, the Web of Science, the Cochrane Library, and Embase for studies comparing TACE + T + I and TACE + T for the treatment of BCLC intermediate- or advanced-stage HCC. The objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and AEs were included as outcomes. We used a fixed- or random-effects model based on the results of a heterogeneity evaluation and performed a meta-analysis using Review Manager 5.3 and Stata 16.0. We then carried out the TSA. RESULTS: Five studies examining a total of 425 patients were included in this study. Our meta-analysis revealed that, compared to TACE + T, TACE + T + I significantly improved the ORR (risk ratio [RR] = 1.53, 95% confidence interval [CI] = 1.27-1.85, p < 0.01) and extended both the median PFS (mean difference [MD] = 4.51 months, 95% CI = 2.16-6.87, p < 0.01) and median OS (MD = 5.75 months, 95% CI = 4.03-7.48, p < 0.01). These results were tested to be true by the TSA without requiring a larger information size. Among AEs, hypertension tended to occur more often in patients treated with TACE + T + I than in those treated with TACE + T (RR = 1.58, 95% CI = 1.05-2.40, p < 0.05). However, the TSA suggested that additional cases are necessary to confirm this difference. Regarding the other AEs, no significant differences were detected between the two groups. CONCLUSION: TACE + T + I showed better effects on the ORR, PFS, and OS than TACE + T as a treatment for BCLC stages B and C HCC, without an obvious increase in the AEs. Based on these findings, well-designed, large RCTs are suggested.


Subject(s)
Carcinoma, Hepatocellular , Chemoembolization, Therapeutic , Liver Neoplasms , Humans , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Immune Checkpoint Inhibitors/therapeutic use , Chemoembolization, Therapeutic/methods
2.
Materials (Basel) ; 16(12)2023 Jun 20.
Article in English | MEDLINE | ID: mdl-37374657

ABSTRACT

In the power plant boiler industry, dissimilar steel welding is widely used in the connection of thermal power generation units. As an important component of the unit, research on the organizational properties of dissimilar steel welded joints has significant guidance for the life design of the joint. For the long-term service state of TP304H/T22 dissimilar steel welded joints, the microstructure's morphological evolution, the microhardness, and the tensile properties of tube samples were analyzed using tests and numerical simulations. The results show that the microstructure of each part of the welded joint was free of damaged features, such as a creep cavity and intergranular cracks. The microhardness of the weld was higher than that of the base metal. In the tensile test, the welded joints broke at the weld metal at room temperature and at the side of the TP304H base metal at a temperature of 550 °C. The tensile fracture morphology demonstrated a change from a ductile fracture to a hybrid fracture when the temperature rose. The fusion zone and base metal on the TP304H side were the stress concentration areas of the welded joint, which easily sprouted cracks. This study holds significant reference value in assessing the safety and reliability of dissimilar steel welded joints in superheater units.

3.
ACS Biomater Sci Eng ; 7(6): 2774-2782, 2021 06 14.
Article in English | MEDLINE | ID: mdl-34030441

ABSTRACT

Biliary-stent implantation has become an effective treatment for patients with malignant obstructive jaundice caused by hepatobiliary carcinoma. Stent restenosis due to tumor ingrowth is a common problem. In this study, we assessed a biodegradable form of magnesium (Mg) for its anticancer effect on hepatobiliary carcinoma, compared to the conventional stent material of titanium (Ti). The results showed that a Mg extract inhibited proliferation and induced apoptosis in human cholangiocarcinoma cells, while a Mg plate inhibited cell adhesion and destroyed the cytoskeleton in the process of biodegradation. In animal experiments with H22 tumor-bearing mice, Mg wires implanted in tumors exhibited an inhibitory effect on their growth compared with Ti wires. Fifteen days after implantation of metal wires, the mean tumor volume and weight in the Mg group were significantly smaller than in the Ti group. We observed the dynamic-degradation process of Mg wires in tumors and generation of H2 gas via soft X-ray photography and scanning electron microscopy. Histopathological analyses showed that apoptosis of tumor cells around Mg wires significantly increased, expression of carbonic anhydrase 9 significantly decreased, and the upstream protein hypoxia-inducible factor 1-alpha also decreased to some extent. Taken together, these results indicated that biodegradable Mg had antitumor properties both in vitro and in vivo, suggesting its potential application as a novel material for biodegradable biliary stents.


Subject(s)
Bile Duct Neoplasms , Cholangiocarcinoma , Animals , Bile Ducts, Intrahepatic , Humans , Magnesium/pharmacology , Mice , Stents
SELECTION OF CITATIONS
SEARCH DETAIL
...